G-protein-coupled receptors (GPCRs) transduce physiological and sensory stimuli into appropriate cellular responses and mediate the actions of one-third of drugs. GPCR structural studies have revealed the general bases of receptor activation, signaling, drug action and allosteric modulation, but so far cover only 13% of nonolfactory receptors. We broadly surveyed the receptor modifications/engineering and methods used to produce all available GPCR crystal and cryo-electron microscopy (cryo-EM) structures, and present an interactive resource integrated in GPCRdb (http://www.gpcrdb.org) to assist users in designing constructs and browsing appropriate experimental conditions for structure studies.
G
PCRs form the largest family of cell-surface receptors, with over 800 members. GPCRs respond to a wide variety of extracellular signals, influencing most branches of human physiology. Thirty-four percent of all drugs approved by the US Food and Drug Administration act on over 100 GPCRs, and clinical trials are currently exploring 300 new GPCR agents and 66 additional orphan GPCRs 1 . The study of GPCR structure-function relationships and their application to rational drug design was long limited by a paucity of high-resolution molecular structures, but breakthroughs in protein engineering and crystallization techniques have led to a surge of structures in the past decade ( Fig. 1) . Today, 271 structures of 53 distinct receptors (plus four species orthologs) have been reported across all four major GPCR classes: A, B1, C and F 2 . Moreover, for classes A and B1, structures of active states are also available, including complexes with an effector G protein [3] [4] [5] [6] or β -arrestin 7 (for class A only). This wealth of GPCR crystal and cryo-EM structures has provided many new functional insights 8 . Direct structural data are increasingly combined with complementary information from nuclear magnetic resonance spectroscopy, double electron-electron resonance, and electron paramagnetic resonance; these techniques have yielded valuable insights into the dynamic conformational landscape of receptors [9] [10] [11] [12] and into their binding interfaces with G proteins 6, 13 and arrestin 7 . However, there are still no structures for the vast majority-87%-of GPCRs, and classes B2 and T lack structures altogether (while having homology to classes B1 and A, respectively). Furthermore, for the majority (52%) of GPCRs there are no close structural templates-from the same receptor family with a shared physiological ligand-that would enable reliable homology modeling (Fig. 1) . Another limitation is the poor representation of active and intermediate receptor states, which are available for only 18 and 12 receptors, respectively (Fig. 1) . Part of the challenge of obtaining GPCR structures is the requirement for protein engineering and the need for tailored protein biochemistry techniques, which have been mastered by only a handful of laboratories worldwide.
In order to expand the knowledge of GPCR function and promote the design of new drugs, it is fundamental to ease the generation of novel GPCR structures-especially of valuable complexes between GPCRs and, for example, signaling-pathway-biased agonists 14 , allosteric modulators 15 , or signaling effector proteins (for example, different classes of G proteins, arrestins, and kinases). To expedite this work, here we provide a comprehensive analysis of all GPCR structure constructs obtained to date. We explore what can be learned from the successful protein-engineering approaches, and investigate which experimental methods and reagents have the most utility or have gained popularity recently in efforts related to GPCR structural biology.
A resource for GPCR structure constructs and experiments
To facilitate the structure determination of GPCRs on a wider scale, we have presented our results in an interactive online resource implemented in the GPCR community hub GPCRdb, which currently serves ~2,500 distinct monthly users with reference data, interactive analysis, and visualization and experiment-design tools. This resource will assist researchers in engineering GPCR constructs and selecting appropriate experimental conditions for crystallography and cryo-EM structure studies. Furthermore, researchers who use GPCR structures for their studies can compare them in a way that is not possible with 'unprocessed' data from the RCSB Protein Data Bank (PDB) or scientific articles. For example, researchers can now select the optimal structural template for their receptor of interest by comparing the underlying construct engineering/integrity or the experimental conditions in which the structure was obtained. The analysis can then be extended through the integrated tools for druggable binding sites [16] [17] [18] and G protein interfaces 19 . Our interactive online resource is integrated as a new "Structure Constructs" section in GPCRdb (Fig. 2 ) 20, 21 . This unique 'structure construct databank' integrates all the GPCR structures in the PDB 22 and residue annotations from SIFTS 23 , plus an extensive manual literature annotation of mutation effects and terminal inserts that h yd rox ytr yp tam ine   5HT 1A  5HT 1B  5HT 1D  5HT 1E 5H T1F  5H T2A  5H T2 B 5H T2 C 5H T4 R 5H T5 A 5H T6 R 5H T7 Li pi d C a n n a b in o id
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aid protein production but are cleaved off before structure determination (Supplementary Note). Furthermore, this resource includes a comprehensive collection of experimental methods and reagents for GPCR structure determination that is amenable to systematic browsing and comparison. It will continue to increase in size and utility as more structures are determined.
GPCR construct engineering
Common GPCR construct engineering strategies. The GPCR crystal structures determined so far have been derived by common protein-engineering strategies. The vast majority of structures have been obtained via N-/C-terminal truncations and mutations, predominantly to increase protein stability (and thus crystal quality), but also to increase expression or to reduce heterogeneity due to glycosylation and palmitoylation (Fig. 3a) . Furthermore, nearly all GPCR structure constructs have been fused to other proteins and peptides to facilitate crystallization and protein production (Fig. 3b) . These modifications can be viewed and compared across receptors in the "Construct alignments" page of the database 24 . The user can switch between wild-type and construct views (Fig. 3c,d ) of the protein and focus on specific selections (for example, receptors with an N-terminal fusion and no deletions in the third intracellular loop (ICL3)). A 'browser view' allows for further focusing by, for example, structure determination method, resolution or release date. Finally, a fourth view provides a sequence alignment detailing truncations, mutations and insertions in the protein construct. Our analysis below of these 'construct alignments' reveals that many modifications have common features and recur at the same positions, which suggests that sufficient templates are now available to allow for data-driven design of new targets of interest.
Active-state crystal structures require an intracellular binding partner. Structures of activated GPCRs are still relatively rare ( Table 2 ). This suggests that solving active states requires more than a simple transfer of working construct-design principles. Indeed, all active-state structures-with the exception of (rhod)opsin-have required an intracellular bound (9 out of 13) and/or fused (4 out of 13) protein to lock them in an active open conformation. These auxiliary proteins include signaling partners such as a G protein (or a fragment thereof) in the A 2A , β 2 -adrenergic, opsin, calcitonin and GLP-1 receptors; arrestin in (rhod)opsin; and nano-/antibodies in the β 2 -adrenergic, μ -and κ -opioid, and M 2 muscarinic receptors (Fig. 4) . Fused proteins have all been placed in ICL3, joining-and presumably locking-transmembrane helices 5 and 6 (TM5-6), which undergo large movements upon activation (Fig. 4) . Several recent developments intended to extend the ability to obtain stable protein complexes 5, 6 , as well as advances in nanobody/antibody production 25 and in structure determination by cryo-EM (see below), are expected to make GPCR active-state and signaling complexes more accessible for those wishing to, for example, obtain complexes with new effectors. The progress in the structural coverage of GPCRs can be followed in the GPCRdb structure statistics 2 , and the utilized ligands and auxiliary (including nanobodies) and fusion proteins are included in the Structure Browser 26 .
Cryo-EM requires little protein modification. The field of cryo-EM has advanced rapidly 27 . The use of phase plates in cryo-EM imaging has increased signal-to-noise ratio 28 and allowed for nearatomic-detail structures of membrane proteins (best resolution of 2.7 Å; ref. 29 ) and GPCR complexes (3.3 Å; ref. 30 ). Cryo-EM is applicable only to large proteins/complexes, but recently the lower size limit was pushed to 64 kDa after the structural determination of hemoglobin 31 . Although the current technology is unlikely to be suitable for the structure determination of seven-transmembrane GPCR monomers, it has delivered structures of eight distinct GPCR-G protein complexes since 2017: calcitonin-G s (Fig. 4) . The engineering of GPCR constructs for cryo-EM is minimal compared with that for crystallography, owing to the lower requirements for conformational homogeneity and stability. GPCR cryo-EM constructs tend to have small truncations in the N terminus, where the native signal peptide is replaced with that of hemagglutinin (or GP67 signal peptide in A 2A -miniG s at both N and C termini. Furthermore, rabbit GLP-1 also features a truncated C terminus and three point mutations 24 , and rhodopsin-G i 5 and μ -opioid-G i 4 also feature truncations at the C terminus. Cryo-EM constructs usually do not require the insertion of fusion proteins; the current exceptions are A 2A -miniG s (with TrxA), rhodopsin-G i (with apocytochrome b 562 RIL (BRIL)) and A 1A -G i (with 22 residues from the M4 muscarinic receptor), all in the N terminus. All these structures were solved in complex with a G protein, as well as nanobodies/antibodies that contributed to the size and stability of the overall complex.
Fusion sites are often transferrable across GPCRs. The majority of GPCR crystal structures have been obtained with the receptor fused to readily crystallizable proteins, which replace flexible/disordered domains and increase the available surface for crystal packing 36 . Our analysis of all fusions 37 showed that the splice sites are located predominantly in the second (for class B/C) and third (for class A/F) intracellular loops (Fig. 5) . Notably, the number of replaced residues in these loops spans from 0 to more than 200. Recently, fusions have also been placed in the N termini of ten receptors spanning all classes. To compare the fusion sites across receptors, we assigned generic residue positions using the GPCRdb numbering, which extends the earlier Ballesteros-Weinstein scheme by correcting for helix bulges and constrictions (ref. 38 and Supplementary Note). This revealed that many fusion sites have been reused for several receptors and are found in coherent clusters in class A (5x65-71 and 6x24-27) and B1 (3x55-58 and 4x36-37) GPCRs. The most frequent fusion sites are found in ICL3 of class A GPCRs-positions 5x69 and 6x25-which have been used in 16 and 15 unique receptors, respectively, representing more than one-third of all (43) class A receptors that have been structurally characterized.
Five different fusion proteins have been used so far in GPCR crystallography (Fig. 5) . T4-lysozyme and BRIL show the widest applicability, spanning 29 and 22 fusion sites, respectively, which suggests that they often are the first choices. In contrast, rubredoxin (CCR5, apelin and P2Y 1 receptors), glycogen synthase (CB 1 and OX 1-2 receptors) and flavodoxin (CB 1 receptor) have been used in only a limited number of cases and at very specific fusion sites in ICL3. Receptors with short loops have, in some cases, been fused to an auxiliary protein without any deletion. In these cases, the use of linkers is more frequent, the most common being one or more iterations of the GS sequence motif, which can serve to either cap an α -helix or provide a flexible and polar spacer. A more exhaustive experimental evaluation is still needed to explore whether less exploited fusion proteins can provide unique uses at specific targets and positions, and to optimize linker length in receptors with short intracellular loops.
Stabilizing mutations have residue bias. Stabilizing GPCR mutations have been generated via conceptually very different approaches, including alanine scanning, structure-based design and divergent evolution. We analyzed mutations obtained with these methods to, where possible, deduce common patterns and rationales for their stabilizing effects. We first analyzed how frequently a specific amino acid had been substituted across all GPCRs (Fig. 6a and ref. 39 ). Notably, we found 150 unique mutations (with respect to receptor and position) that reveal a wide spectrum of amino acid substitutions. Among the wild-type residues, G/L/S/T/V have been replaced ten or more times, whereas P/Q/W have been replaced only one or two times. The most frequently introduced amino acid is, as expected, alanine, whereas H/T and D/P/R/S have been introduced no and one time, respectively. This shows that although stabilized GPCRs share the canonical residue alphabet, they have different residue usage (i.e., amino acid composition) than wild-type receptors. This is consistent with specialized roles of the mutated residues in conforming to evolutionary constraints, molecular structure and protein function, and is analogous to two different languages that use the same alphabet but combine and use the letters in unique words with specific meanings. Deciphering the 'thermostability' language might help scientists focus alanine scans and formulate rational mutagenesis strategies that exploit a wider set of amino acids. The largest group of stabilizing mutations comes from alanine scanning (59% when including five A> L), a 'brute force' technique that typically does not have a predefined rationale. We analyzed all 83 alanine mutations across the complete construct sequences to determine whether the success has been different among amino acid types. We found that the most frequently substituted residues are L, S and T (10 or 11 mutations), closely followed by G and V (8 mutations), which all represent small amino acids. In contrast, the least substituted residues are large and/or polar: D, H, N, P and W (one mutation); and E, Q and R (two mutations)-with one exception, C. This pattern correlates well with traditional evolutionary substitution matrices, but not with an increased helical propensity 40 as could be expected, as GPCRs consist largely of helices including the transmembrane domain, helix 8 (H8) and often ICL1-2. Alanine has the greatest propensity to form α -helices, whereas G and P have the second-lowest and lowest propensity, respectively. This could explain the many substitutions of glycine residues, which also induce the most backbone flexibility, but not the single replacement of P and most of the amino acids with intermediate helix propensity. Prolines almost exclusively appear in transmembrane helical segments of GPCRs when they are important for receptor structure and/or function; therefore, it is expected that mutation of a proline would not be well tolerated. Indeed, the only proline mutant in crystallized constructs (P6x42a/P6x47b in GLP-1) showed impaired activity compared with that of the wild type (Extended Data Fig. S2 in ref. 41 ). In summary, although alanine scanning is a successful stabilization method, more thorough analyses that factor in the wild-type residue (for example, the most frequently mutated small amino acids L, S, T, G and V), positions shown to stabilize multiple receptors/ families (next section) and the local environment (for example, consensus contact networks in the transmembrane bundle 42 ) of each mutation could assist in focusing this technique.
Stabilization across receptors/families. We next investigated the receptor topology and specific receptor positions for all 150 stabilizing mutations to elucidate crucial receptor regions and positions shown to stabilize multiple receptors/families. We found that the stabilizing mutations were distributed across all seven transmembrane helices, as well as the N terminus, loops and H8 (Fig. 6b,c) . In the transmembrane helices, TM3 features the greatest number of mutations, whereas TM1 and TM4 have the fewest. This trend reflects their relative positions in the transmembrane bundle, in which TM3 is central and packs to four other helices, whereas TM1 and TM4 are more peripheral and interact primarily with only two other transmembrane helices. To facilitate an efficient and clustered residue-position-specific investigation, we developed a 'Stabilizing Mutation Analyser' that can group mutations in different receptors on the basis of a common generic residue position and wildtype and/or mutant amino acids 43 . The tool also maps mutations to known functional receptor sites and calculates how the amino acid substitution changes sequence conservation, helix propensity and hydrophobicity. Leveraging this tool, we uncovered 25 positions that have stabilized more than one receptor, with 13 also stabilizing different receptor families (Supplementary Table 2 and Fig. 6c) .
We proceeded to investigate the underlying rationale for the reused stabilization sites. The first of such mutations, 3x41W, has been used in six GPCRs. 3x41W packs to TM3-5 44 , including the highly conserved P5x50 in TM5. A second mutation, 3x34A, seems to have an indirect effect by allowing W4x50 in TM4 to pack between the transmembrane bundle instead of facing the membrane interface. A third position, 6x48, contains a highly conserved aromatic residue that packs to TM3, TM6 and TM7 (I3x40, F6x44 and T7x41). Whereas classes A, B2 and C have primarily a W at this TM1   TM2   TM3   TM4   TM5   TM6   TM7   H8   ICL1 ECL2 ECL3 N term.
Fig. 6 | Substitution frequencies, structural mapping and rationale for stabilizing mutations. a, Amino acid substitution matrix for all 150 stabilizing GPCR mutations. The frequencies represent the number of distinct GPCRs and residue positions (merging multiple structures or orthologs) to optimally reflect the transferability across the GPCR superfamily. The different usage of the amino acid alphabet among wild-type (rightmost column) and mutant (bottom row) residues is indicated by the grayscale color-coding. Grayscale is also used to illustrate the success of alanine mutants (second column) when substituting mainly similar (small and/or aliphatic hydrophobic) amino acids. b, Distribution of stabilizing mutations 43 across receptor segments, spanning all seven transmembrane helices, the N terminus, three loops and H8. ECL, extracellular loop. c, Mapping of all stabilizing mutations and their structural rationale onto the β 2-adrenoceptor (PDB 3SN6) using the GPCRdb generic residue indexing 38 . Incl., including.
position (for example, 68%/16%/3% WFY in class A), class B1 contains mainly F, Y or, alternatively, E, which instead forms a charged/ polar interaction to residues in TM2, TM5 and TM7 (2x53, 5x44 and 7x45, respectively). Stabilizing construct mutations in this region have been placed in 6x48 (apelin and glucagon receptors), 3x40 (β 1 -adrenoceptor and apelin receptor), 6x47 (GLP-1) and 7x41 (adenosine A 2A and neurotensin 1 receptors). Furthermore, a sodium ion binding site is present in the transmembrane bundle of several class A receptor structures, immediately below the transmembrane ligand binding pocket 45 . The sodium ion acts as a negative allosteric modulator by stabilizing the inactive conformation, whereas its binding site collapses upon activation. Hence, the mutation in the sodium ion binding site D7x49N in P2YR 1 and P2YR 12 weakens the inactive state and stabilizes intermediate-state structures.
Certain GPCR residues-activation switches-rearrange their side chains to form unique stabilizing contacts in inactive or active states [46] [47] [48] . For instance, R3x50, part of the conserved DRY motif of TM3, interacts with E3x49A in the inactive state and, upon activation, swings toward the transmembrane bundle core to form the 'ceiling' of the G-protein-binding site 3 . This switch has been modulated by the mutations R3x50L and E3x49A to stabilize agonistbound and active-state-like NTS 1 structures, and also by the nearby mutation L6x37A in the A 2A and NTS 1 inactive/intermediate-state structures. In the active state, another switch, Y5x58, swings toward the transmembrane bundle to form a polar contact with R3x50 in the DRY motif. Y5x58F/A mutations have been used to stabilize β 1 and FFA 1 inactive-state structures. An additional activation switch, Y7x53ax57b in the NPxxY motif of TM7, forms, in the inactive state, hydrophobic and aromatic contacts with TM2 (2x43ax50b) and, in class B1, also a hydrogen bond to T6x37ax42b. In active-state class A structures, this residue swings into the G protein site (above R3x50) to form hydrophobic contacts to TM3 (3x43 and 3x46) and a direct or water-mediated hydrogen bond to the backbone of TM6. Thermostabilizing mutations of these motifs have been introduced in 7x53 (β 2 -adrenoceptor and CRFR1) and 3x46 (CB 1 ). Finally, Y/K6x30ax35b in TM6 has been mutated to alanine in most inactive-state structures of class B1 receptors to allow TM6 to pack more tightly with TM3 and TM5 on the intracellular side. In the inactive state of the glucagon receptor, K6x30ax35b forms a salt bridge to D6x28ax33b (all class B GPCRs have a proximal negatively charged residue), and in the intermediate state GLP-1 structure 41 , K6x30 swings toward the backbone of the last residue in TM7 (7x56ax60b).
Understanding the rationale behind these mutations allows our construct-design tool ( Fig. 2 and below) to suggest stabilizing mutations, as well as constructs for the many receptors that lack a close template (Fig. 1) .
N-/C-terminal truncations.
Truncation of flexible regions in the N and C termini of GPCRs aids the formation of well-ordered diffracting crystals. To study the extent and variation of such deletions, we developed a truncation-site analysis tool 49 that maps the truncated and preserved N-and C-terminal segments. The lengths of the N and C termini are defined as the number of residues before TM1 and after H8, respectively. Strikingly, the length of preserved N termini in class A GPCRs spans from 0 to 50 residues. About half of the receptors have been obtained without any N-terminal truncation or with deletion of only the initial methionine start codon to avoid transcription. Class B1, C and F GPCRs have structured N termini that comprise the binding domains of their physiological ligands, and such elements are typically either completely truncated or left unaltered. Full-length structures have been obtained for classes B1 and F, but not C. Furthermore, constructs for the same receptor family, or even the same receptor, often also show large variation in N-terminal lengths, which suggests that the truncation sites may vary with other factors, such as the choice of tags and signal peptides. Taken together, this shows that N-terminal truncations may be difficult to infer for a new target, but on the other hand, there are often multiple viable sites.
Furthermore, we investigated how the putative flexibility or rigidity of N termini is actually reflected in the truncations. To this end, the truncation-site analysis tool shows a color-coded map of flexible, rigid and context-dependent regions predicted with Dynamine 49, 50 . As presumed, the vast majority of the truncated segments in class A GPCRs are predominantly flexible. However, the 5-HT 2C and CB 1 receptors are truncated closely after segments predicted to be rigid, which indicates that it might be possible to preserve a larger part of their native termini. Also as expected, the preserved parts of the N termini in class A GPCRs are predominantly rigid, although there are several exceptions. Finally, inspection of the structures with the longest N termini-those with more than 30 preserved residuesshowed that five out of seven receptors contain a secondary structure element that could reduce flexibility (Supplementary Table 3 ). This suggests that preservation of such elements might be advantageous for structure determination with both crystallography and cryo-EM. Thus the prediction of protein flexibility could complement the site/length-based rationale for N-terminal truncations, especially for targets without a close structural template.
Unlike the N termini, the vast majority of preserved C-terminal segments are short (up to 12 residues) and contain clusters of recurring truncation sites, demonstrating that these are transferrable across GPCRs. Furthermore, fewer class A GPCRs have been obtained with a wild-type C terminus than with an N terminus (one-third versus one-half, respectively). In the other end of the spectrum, four receptors-P2Y 1 , CCR5, calcitonin and squid rhodopsin-have long C termini (> 30 residues), but only the longest (squid rhodopsin, with 118 amino acids) contains rigid segments. Class B1 GPCRs have a long H8, and a comparison of the constructs showed that the GLP-1, glucagon and CRFR1 receptors have sometimes been truncated before the C terminus at 9, 12 and 19 positions into H8, respectively.
online GPCR construct design tool
We developed an online construct-design tool (Fig. 2) that allows the user to generate complete construct sequences for any GPCR and type of modification, with the goal of supporting structural determination on a wider scale by reducing the total number of constructs that need to be experimentally screened. Up-to-date instructions and an explanatory video are integrated at the top of the tool page.
Application modes. The first application mode, 'Truncation/fusion scan' , allows users to enter several N-/C-terminal truncation and protein-fusion start/end sites either automatically, by defining a number of top-ranked sites, or by manual inspection of the suggestions. Suggested N-/C-terminal truncation and fusion-protein sites are ranked first on the basis of target-template homology (i.e., those in the same receptor, receptor family or class) and then by their frequency (the number of distinct GPCRs with a structure exploiting the given site). For long N termini it is possible to replace only the signal peptide, predicted with SignalP 51 . Suggested N-and C-terminus truncation sites/lengths are defined as the number of preserved residues before the start of TM1 and after the end of H8, respectively (the data exclude termini with a fusion protein). Loop fusions are placed in ICL2 and ICL3 for classes B and C, and A and F, respectively (Fig. 6) . If the user does not select a loop fusion, long ICL3 loops (more than eight residues) are instead assigned suggested deletions from nonfused and N-terminally fused constructs. Suggested fusion sites can be filtered by the type of fusion protein used. Finally, in a truncation/fusion scan, the rightmost part of the construct table has a section to "add known stabilising mutations to all constructs. " This allows the user to manually enter mutations found to be stabilizing in previous experiments to all constructs already listed in the table. If the target receptor already has a published structure containing such mutations, those mutations are also listed as suggestions. The tool generates constructs for all unique combinations of selected truncation/fusion sites.
A second application mode, 'Mutation scan' , first designs just one reference construct-which can include mutations with known stabilizing effects-and then selects a number of stabilizing mutations that are individually added to generate as many constructs. Predicted stabilizing mutations can be either hand-picked or added in batches through specification of a fixed number of top-listed suggestions in the construct table column "Scan predicted mutations in separate constructs. " Predicted stabilizing mutations are assigned priorities according to their rationale (see below); some are distinct for inactive or active conformational states (and can be filtered before selection).
A third application mode, 'Custom constructs' , can be used to manually modify constructs generated from the Truncation/fusion scan or Mutation scan applications, or to design de novo constructs. For any application, N-/C-terminal insertions and mutations of glycosylation and palmitoylation sites must be selected individually. Finally, the sequence and site of any modification can be customdefined by the user, for example, to incorporate an in-house-validated mutation, alternative tag or modified fusion protein at a specific residue position. Constructs can be inspected in a snake plot and saved in a spreadsheet for ordering of cDNAs or to resume the design later.
Suggested stabilizing mutations. The suggested stabilizing mutations span a number of specific design rules 52 that are both dataand rationale-driven and cover five overall concepts. (1) Homology: this concept infers a mutant position and amino acid if the target is the same receptor or a member of the same receptor family. For classes B-F, which are smaller and have less data than class A, mutations will also be informed from any member of the same class. (2) Common mutations: these are mutations that have been used within several distinct receptor families, but not yet in that of the selected receptor target. (3) Conservation: this concept introduces residues that are missing in the target but at least 70% conserved in the receptor family or class. For the positively charged residues H, K and R, a lower conservation threshold (40%) is used in order to incorporate multiple positions at the ends of the transmembrane helices from which these residues can interact with the polar head groups of the cell membrane. Furthermore, the low-propensity residues G and P are treated separately (below), and C, which can form disulfide bridges, is excluded. (4) Helix propensity: this concept aims to increase helix propensity by replacing G and P residues that are present in the target receptor but poorly conserved in the receptor family or class to alanine. G residues in four positions from a helix end are preserved, as they can be crucial for the transition to a loop structure. (5) State switches: these residues form interactions that are unique for either inactive or active receptor states. The state selected by the user will be targeted via the addition and/or removal of residues with such interactions.
Application of the construct-design tool to 5-HT 2C . The construct-design tool has already been used for some time by the GPCR Consortium (http://gpcrconsortium.org), academic labs, and companies whom we have assisted in setting up local versions to incorporate their proprietary data 53 . To demonstrate the tool, we tested the thermostability of 17 single-point mutants of the serotonin receptor 5-HT 2C (Supplementary Note). The melting temperature of the designed constructs was increased by at least 2 °C in 71% (12/17) of the mutants (Supplementary Table 4 ). However, we observed vastly different success rates depending on the ligand tested (no ligand (apo), 53% (9/17); antagonist (ritanserin), 18% (3/17); in-house agonist (N-(4-bromo-2,5-dimethoxyphenethyl)-1-(2-methoxyphenyl)ethan-1-amine), 12% (2/17); partial agonist (ergotamine), 6% (1/17)). The higher success rate for the apo form indicates that the ligands-which all have, in this case, a thermostabilizing effect (ref. 54 and data not shown)-may be masking the inherent effect of the mutation. However, the selection and, particularly, the combination of a more stringent selection of thermostabilizing mutations would be likely to match or surpass the thermostabilizing effect of the ligand. Furthermore, only one mutation in our set-V185I 4x56 -increased the stability in two ligand experiments, in line with the ligand specificity of stabilizing mutations often observed in previous studies 55 . This limited assessment of our prediction of thermostabilizing mutations can be deemed encouraging, considering that the construct-design tool typically suggests 30-50 stabilizing mutations per construct. However, ongoing validation will lead to a refined prioritization of the suggested mutations. This will also allow us to reduce the number of mutations that need to be tested experimentally, and hence also further improve the success rate.
Survey of methods used in GPCR structure determination
Our extensive annotation of experimental data from GPCR structure publications is made available in the GPCRdb Experiment Browser page 56 . This tool allows for swift navigation and filtering of methods and reagents for protein expression, purification and preparation of samples for structure determination by crystallography or cryo-EM. Researchers can quickly and easily infer the most relevant conditions for their experiments from related receptors and keep track of the development of new methods and materials.
Method and reagent utility and trends. Expression. Currently, only bovine and squid rhodopsin have been obtained as native protein from natural sources. Most GPCRs have been obtained through recombinant expression in insect cells (Fig. 7a,b) , predominantly in the Sf9 cell line, which was the expression system of choice for the first crystallized non-rhodopsin GPCRs (Fig. 7a, bottom) . However, in the past 2 years an increased number of GPCRs have been expressed in mammalian systems; for example, the rhodopsin, CB 1 . The hemagglutinin signal peptide is most frequently used to increase GPCR expression. Ligands are also often added at this stage to improve expression and protein stability 57 .
Purification. His and Flag tags are the most common purification tags used for GPCR structural biology experiments (Fig. 7c) . Purification of GPCRs for structural studies is carried out mostly from protein solubilized in dodecyl-maltoside (see below) by immobilized-metal-ion affinity chromatography, using a C-terminal poly-histidine tag, or by antibody-affinity chromatography, using an N-terminal Flag tag. Both tags can be used simultaneously to obtain higher-quality samples 58 and are usually later removed by proteases targeting engineered proteolytic cleavage sites (HRV 3C/PreScission or TEV, used with similar frequencies) (Fig. 7d) . Some but not all laboratories use size-exclusion chromatography as an additional last purification step.
Structure determination. More than 90% of all GPCRs have been crystallized in lipidic mesophases (mostly cubic, but also sponge phases) (Fig. 7e) , using almost exclusively mono-olein (9.9 monoacylglycerol (MAG)); only about ten structures have been crystallized from other cubic-phase lipids (9.7, 11.7 and 11.9 MAG). The vast majority of these structures have also been obtained with 10% cholesterol used as an additive to the lipidic mesophases. Crystallization from lipidic mesophases is achieved with protein solubilized in dodecyl-maltoside (DDM; ~60%), lauryl maltoseneopentyl glycol (LMNG; ~30%) or decyl-maltoside (DM; ~12%) (Fig. 7f) , with cholesterol hemisuccinate (CHS) as an additive and PEG 400 as the most common precipitant (~70%) (Supplementary Table 5 ). Another strategy used recently is solubilization in DDM and subsequent replacement with LMNG before crystallization. HEGA-10 (decanoyl-N-hydroxyethylglucamide) and methyl-ester sulfonate have also been used, but only in a small number of cases.
Only about 13% of GPCRs (rhodopsin and the β 1 -adrenergic, adenosine A 2A and neurotensin 1 receptors) have been crystallized by vapor diffusion (Fig. 7e) . The conditions for crystallization by vapor diffusion are more diverse (Supplementary Table 5 ) and include the use of harsher detergents (e.g., octyl-and nonyl-glucosides), alternative lipids (such as brain lipid extract), higher-molecular-weight PEGs and alternative precipitants. Vapor diffusion can succeed in a broader pH range (Fig. 7g) and at lower temperatures than lipidic cubic phase, and also allows for lower protein concentrations (Fig. 7h) . Most of the receptors crystallized by vapor diffusion have also been crystallized in lipidic mesophases (Fig. 7e) , usually yielding better-diffracting crystals. Hence, crystallization from lipidic mesophases appears to be a more general method, whereas vapor diffusion has been the initial method of choice for a few selected targets that, in the end, seemed amenable to crystallization in lipidic mesophases after optimization.
Finally, cryo-EM requires a very low protein concentration (~1 mg/ml) compared with that needed for crystallization (~20-80 mg/ml) (Fig. 7g) and allows for the use of mild detergents for solubilization. Especially for GPCR complexes, which often require a complicated purification procedure and are hard to produce in large amounts, cryo-EM certainly is advantageous. The choice of detergent is quite limited, and only mild detergents can keep the complex stable 27 . DM 35 , DDM supplemented with CHS 5, 6 , and LMNG without 28 or with CHS 30, 33 are used to solubilize cell membranes, and the complexes are purified in the last step with DM 35 , digitonin 6 , or LMNG without 28 or with lipidic supplements 4, 5, 30, 32, 33 . Directed evolution has improved GPCR expression. Receptor expression varies largely 59 , and insufficient protein yields hamper crystallization screens and X-ray diffraction and cryo-EM experiments. Forty-two mutations in GPCR crystal structure constructs have been reported to increase surface expression, of which only seven have also been reported to be thermostabilizing (however, this has not always been tested, and the total number is likely to be higher). Thirty-two of these mutations were identified via a directed evolution method for increasing GPCR expression. In contrast, only four are mutations to alanine, which suggests that alanine scanning is not an efficient technique for increasing surface expression. Seventeen mutations have introduced aliphatic residues (A, 4; L, 7; M, 1; V, 6), which have high helix propensity, and especially L and V are known to stabilize helices through contact with the next helical turn 60 . Furthermore, nine mutations have introduced positively ionizable residues (R, 6; K, 2; H, 1). Our structural investigation shows that these are located at the height of the membrane surface and thus are likely to anchor the receptor through salt bridges to the polar head groups. In all, this uncovers a distinct rationale for the most common types of receptor-expression-increasing mutations, whereas others ought to be revisited when more such mutations have become available. Removal of glycosylation and palmitoylation sites sometimes aids crystallization. Removal of certain post-translational modifications can improve protein homogeneity and, therefore, the chances of crystal formation. Our Mutation Browser 61 provides a comprehensive annotated list of all construct mutations and their effects. Our analysis showed that 15 glycosylation sites have been removed from the extracellular interface of nine receptors. Thirteen mutations removed a glycosylated N residue, and two were of T, which is present in both O-and N-linked glycosylation consensus motifs (S/TS/TX 1-10 N and NXS/T, respectively). Glycosylations are often removed enzymatically during the protein-purification steps. Furthermore, seven palmitoylation sites, which function as anchors to the cell membrane, have been deleted in or after H8 in four receptors. However, the fact that most structures have been obtained without removal of post-translational modifications suggests that it is desirable, when possible, to preserve these sites, which can increase receptor expression and stability.
outlook
We expect that the lessons learned from our extensive comparison of all available GPCR constructs and the accompanying online platform will assist the community in accelerating the determination and assessing the quality of GPCR structures. Given the role of these membrane proteins as major signaling mediators and therapeutic targets, we expect that our study will impact both basic understanding of receptor-structure function and prospects for attaining new templates for structure-based drug development.
